Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy.
Clin Transl Oncol
; 22(11): 2130-2135, 2020 Nov.
Article
en En
| MEDLINE
| ID: mdl-32232716
ABSTRACT
PURPOSE:
To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs). METHODS/PATIENTS We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.RESULTS:
NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively).CONCLUSIONS:
NLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfocitos
/
Neoplasias Urológicas
/
Urotelio
/
Inhibidores de Puntos de Control Inmunológico
/
L-Lactato Deshidrogenasa
/
Neutrófilos
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Clin Transl Oncol
Año:
2020
Tipo del documento:
Article